A detailed history of Federated Hermes, Inc. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 572,083 shares of AVIR stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
572,083
Previous 571,268 0.14%
Holding current value
$1.82 Million
Previous $1.89 Million 1.38%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.17 - $4.02 $2,583 - $3,276
815 Added 0.14%
572,083 $1.92 Million
Q2 2024

Aug 08, 2024

SELL
$3.31 - $4.04 $301 - $367
-91 Reduced 0.02%
571,268 $1.89 Million
Q1 2024

May 14, 2024

SELL
$3.09 - $4.56 $75,188 - $110,958
-24,333 Reduced 4.08%
571,359 $2.31 Million
Q4 2023

Jan 31, 2024

SELL
$2.8 - $3.35 $36,663 - $43,864
-13,094 Reduced 2.15%
595,692 $1.82 Million
Q3 2023

Nov 13, 2023

SELL
$3.0 - $3.79 $15,612 - $19,723
-5,204 Reduced 0.85%
608,786 $1.83 Million
Q2 2023

Aug 14, 2023

SELL
$3.21 - $5.06 $4.57 Million - $7.21 Million
-1,425,066 Reduced 69.89%
613,990 $2.3 Million
Q1 2023

May 08, 2023

SELL
$3.0 - $4.97 $3.13 Million - $5.18 Million
-1,041,841 Reduced 33.82%
2,039,056 $6.83 Million
Q4 2022

Feb 13, 2023

SELL
$4.35 - $6.17 $2.37 Million - $3.37 Million
-545,921 Reduced 15.05%
3,080,897 $14.8 Million
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $212,391 - $340,058
38,687 Added 1.08%
3,626,818 $20.6 Million
Q2 2022

Aug 15, 2022

BUY
$5.33 - $8.18 $8.19 Million - $12.6 Million
1,536,799 Added 74.92%
3,588,131 $25.5 Million
Q1 2022

May 13, 2022

BUY
$5.5 - $9.19 $11.3 Million - $18.9 Million
2,051,332 New
2,051,332 $14.8 Million

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.